Clinical trials: Chimera
Neuroblastoma, Sarcoma
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
The purpose of this study is to test the manufacturing feasibility and safety of intravenous (IV) administration of B7-H3CART in children and young adult subjects with relapsed and/or refractory solid tumors expressing B7-H3…
- Conditions
- Neuroblastoma, Sarcoma, Osteosarcoma
- Trial name
- NCT06500819
- Testing
- B7-H3CART Dose (Intravenous)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Acute Myeloid Leukemia, Chimeric Antigen Receptor T-cell
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Universal CLL1 Chimeric Antigen Receptor T-Cell in Relapsed/Refractory Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a common type of acute leukemia in adults. Although the treatment of AML has improved in recent decades, the 5-year survival rate remains below 50% due to the chemoresistance or toxicity of these…
- Conditions
- Acute Myeloid Leukemia, Chimeric Antigen Receptor T-cell, Universal CLL1 CAR-T
- Trial name
- NCT07432100
- Testing
- universal CLL1 CAR-T cells
- Volunteers
- 20 people
- Sponsor
- Mingfeng Zhao
B-cell Acute Lymphoblastic Leukemia
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
This is a single-center, open-label, single-arm prospective study designed to evaluate the safety, tolerability, and efficacy of dual-target CD22/CD19 chimeric antigen receptor (CAR)-T cell therapy as consolidation treatment in…
- Trial name
- NCT07575919
- Testing
- CD22/CD19 Dual-Target CAR-T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Liping Dou
Relapsed Neuroblastoma, Refractory Neuroblastoma
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma
- Trial name
- NCT03635632
- Testing
- C7R-GD2.CART cells
- Where
- 2 sites in United States
- Volunteers
- 94 people
- Sponsor
- Baylor College of Medicine
Arthritis, Rheumatoid
Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027)
This is an open-label program of Remicade in the treatment of patients with active rheumatoid arthritis (RA) despite treatment with methotrexate (MTX) to determine the onset of efficacy of infliximab.
- Trial name
- NCT00794898
- Testing
- Infliximab (Remicade)
- Volunteers
- 19 people
- Sponsor
- Merck Sharp & Dohme LLC
Alveolar Soft Part Sarcoma
GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02)
CLIC-YYC-GPNMB-02 is a Single Patient Study (SPS) developed according to the Health Canada template and guidelines released in 2019 for studies to access therapies not otherwise available to patients, in the situation where there…
- Trial name
- NCT06789081
- Testing
- GCAR1
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- AHS Cancer Control Alberta
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
This phase I trial tests the safety, side effects, and best dose of allogeneic CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs) in treating patients who have chronic graft versus host disease (cGVHD) after an…
- Conditions
- Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
- Trial name
- NCT05993611
- Testing
- Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL)
ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
This Phase 1, single centre, open label dose escalation study aims to identify a safe dose of third-generation anti-CD19 CAR T-cells (WZTL-002) in the treatment of patients with relapsed or refractory (r/r) B-cell Non Hodgkin…
- Conditions
- Lymphomas Non-Hodgkin's B-Cell, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)
- Trial name
- ENABLE-1 (NCT04049513)
- Testing
- WZTL002-1 (1928T2z CAR-T cells), Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
- Where
- New Zealand
- Volunteers
- 30 people
- Sponsor
- Malaghan Institute of Medical Research
Multiple Myeloma
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Treatment for relapsed/refractory multiple myeloma continues to evolve with the approval of highly effective anti-BCMA CAR T therapies in recent years.
- Trial name
- NCT06623630
- Testing
- Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Gastric Cancer, Colon Cancer
Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer
- Trial name
- NCT05538195
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Lymphoma, B-Cell, Autologous Stem Cell Transplantation
Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma
The study is designed to evaluate the efficacy and safety of chimeric antigen receptor T-cell therapy following autologous stem cell transplantation for relapsed/refractory B-cell Non-Hodgkin's lymphoma.
- Trial name
- NCT06381830
- Testing
- Apheresis, Autologous Stem Cell Transplantation, CAR-T Cell Therapy
- Where
- China
- Volunteers
- 8 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, B-Cell
A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
In the conventional treatment options, B cell leukemia could be treated with chemotherapy drugs or HSCT. But chemotherapy could barely cured leukemia.
- Trial name
- NCT02672501
- Testing
- anti-CD19-CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
HIV/AIDS
The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist…
- Trial name
- NCT03240328
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangzhou 8th People's Hospital
Multiple Myeloma
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
The study is an early, open, single-centered trial. The purpose of this study is to evaluate the safety and persistence of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM.
- Trial name
- NCT04182581
- Testing
- BCMA/CD19 Dual-Target CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Xijing Hospital
Malignant Ascites, Cancer
A Study of M701 (EpCAM and CD3) in Malignant Ascites
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
- Trial name
- NCT04501744
- Testing
- Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Cancer
A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.
- Trial name
- NCT06701201
- Testing
- SynKIR-110, SynKIR-310
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Verismo Therapeutics
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and…
- Trial name
- NCT07564401
- Testing
- DJI136
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Cervical Cancer
Intervention of CAR-T Against Cervical Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cells immunotherapy in patients who have GD2, PSMA, Muc1, Mesothelin or other markers positive cervical cancer.
- Trial name
- NCT03356795
- Testing
- Cervical cancer-specific CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Healthy Donors, Myeloproliferative Diseases
CAR-NK Cells Production and Expansion From Patients With Lympho or Myeloproliferative Disorders and From Healthy Donors
Recent studies demonstrated the safety and efficacy of allogeneic and autologous infusion of NK cells as adoptive immunotherapy in malignant hematological diseases and solid tumors.NK cells are innate immunity effectors with…
- Conditions
- Healthy Donors, Myeloproliferative Diseases, Lymphoproliferative Disorders
- Trial name
- NCT06727383
- Testing
- peripheral blood collection, leukapheresis
- Where
- Italy
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
B Cell ALL, B-Cell Lymphoma
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.
- Conditions
- B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
- Trial name
- NCT04148430
- Testing
- Anakinra
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center